---
schema_version: "secwatch.filing_event.v1"
accession: "0001213900-22-082228"
form_type: "8-K"
ticker: "CTXR"
cik: "0001506251"
company_name: "Citius Pharmaceuticals, Inc."
filed_at: "2022-12-22T23:59:59+00:00"
generated_at: "2026-06-21T00:01:51.661201+00:00"
event_type: "earnings"
sentiment: "neutral"
materiality_score: 0.6
calibrated_materiality_score: 0.6
confidence: "high"
source: SEC EDGAR
---

# Citius Pharma reports FY2022 net loss $33.6M; cash $41.7M, I/ONTAK PDUFA July 2023

## Summary
- Net loss $33.6M ($0.23/shr) vs $23.1M ($0.23/shr) prior year; R&D expenses up $5.5M to $17.7M.
- Cash and equivalents $41.7M as of Sept 30, 2022; estimated runway through December 2023.
- I/ONTAK BLA accepted by FDA; PDUFA target action date set for July 28, 2023.
- Mino-Lok Phase 3: 169 patients enrolled, 72 of 92 failure events achieved, 17 patients pending.
- Halo-Lido Phase 2b enrollment ongoing; data readout expected in second half 2023.

## SEC filing metadata
- accession: 0001213900-22-082228
- form_type: 8-K
- ticker: CTXR
- cik: 0001506251
- company_name: Citius Pharmaceuticals, Inc.
- filed_at: 2022-12-22T23:59:59+00:00
- event_type: earnings
- sentiment: neutral
- materiality_score: 0.6
- calibrated_materiality_score: 0.6
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1506251/000121390022082228/0001213900-22-082228-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1506251/000121390022082228/ea170685-8k_citius.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001213900-22-082228
- JSON: https://secwatch.observer/filing/0001213900-22-082228.json
- Plain text: https://secwatch.observer/filing/0001213900-22-082228.txt

## Key facts
- Earnings Releases
  Citius Pharmaceuticals, Inc. reported the fiscal full year ended September 30, 2022 results: net income $33.6 million, EPS ($0.23) per share.
  - Period: the fiscal full year ended September 30, 2022
  - Net income: $33.6 million
  - EPS: ($0.23) per share
  - Result: reported results
  source text: Net loss was $33.6 million, or ($0.23) per share for the full year ended September 30, 2022 compared to a net loss of $23.1 million, or ($0.23) per share for the full year ended September 30, 2021.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1506251/000121390022082228/0001213900-22-082228-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.